Drugs / HNC664
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04504448 | Aug 2020 → Jul 2021 | — | Guangzhou Henovcom Bioscience Co. Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HNC664 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04504448 ↗ |
| Known as | HNC664 capsules | “HNC664 capsules” NCT04504448 ↗ |
| Route | Oral | “PO,starting dose of 40mg escalating up to 500mg” NCT04504448 ↗ |